SCHEMBL4904048

SCHEMBL4904048

CCCOc1c(-c2ccccc2)nc(N)nc1N1CCSCC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.41
CYP1A2 P05177 2/20 0.41
CYP2C9 P11712 2/20 0.41
CYP2C19 P33261 2/20 0.41
NPSR1 Q6W5P4 2/20 0.41
POLB P06746 1/20 0.41
ALDH1A1 P00352 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
HRH4 Q9H3N8 4/20 0.38
TP53 P04637 1/20 0.38
ADORA2A P29274 4/20 0.37
ADORA1 P30542 4/20 0.37
RAB9A P51151 2/20 0.37
NPC1 O15118 1/20 0.37
AR P10275 1/20 0.36
ADORA3 P0DMS8 1/20 0.36
ADORA2B P29275 1/20 0.36
HRH3 Q9Y5N1 1/20 0.36
DHFR P00374 1/20 0.36
NOS1 P29475 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4900894 0.91 L3MBTL1 (0.45) L3MBTL1CYP1A2CYP2C9CYP2C19NPSR1
SCHEMBL4907732 0.70 ADORA2A (0.37) ADORA2AADORA1DHFR
SCHEMBL4565139 0.66 TP53 (0.52) L3MBTL1CYP1A2CYP2C19ALDH1A1TP53
SCHEMBL27738433 0.66 HRH4 (0.62) NPSR1POLBHRH4ADORA2AADORA1
SCHEMBL4904056 0.65 ADORA1 (0.39) ADORA2AADORA1ADORA3ADORA2B
SCHEMBL4900919 0.65 ADORA1 (0.47) POLBADORA2AADORA1ADORA3ADORA2B
SCHEMBL4904064 0.64 HRH3 (0.48) ADORA2AADORA1ADORA3ADORA2BHRH3
SCHEMBL4735759 0.64 HRH4 (0.57) HRH4ADORA2AADORA1HRH3MAPT
Ethylamine SCHEMBL27882003 0.63 ADORA1 (0.60) NPSR1ALDH1A1ADORA2AADORA1AR
SCHEMBL4904708 0.62 ADORA2A (0.49) L3MBTL1NPSR1ALDH1A1ADORA2AADORA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8349859-B2 Pyrimidine derivatives HUTCHISON MEDIPHARMA ENTERPRISES LIMITED (BS) 2013-01-08 US disclosed
US-20080255172-A1 N4-(2-methyl-1H-indol-5-yl)-N2-phenylpyrimidine-2,4-diamine; angiogenesis related disorder like cancer or age-related macular degeneration HUTCHISON MEDIPHARMA ENTERPRISES LIMETED (BS) 2008-10-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080255172-A1 N4-(2-methyl-1H-indol-5-yl)-N2-phenylpyrimidine-2,4-diamine; angiogenesis related disorder like cancer or age-related macular degeneration CCND2, KDR, FLT4 L3MBTL1 419/4885CYP1A2 3843/4885CYP2C9 4039/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.